FGFR4 and hepatocellular carcinoma: In this study, we used PD173074, an inhibitor of FGFR4, to explore the role of FGFR4 and the underlying mechanism in HepG2 and Hep3B cell lines, and our results suggest that FGFR4 is involved in the proliferation of HCC via ERK/CUL3/cyclin E axis and this finding provides potential therapeutic targets for HCC.